



cancer conference
ncri
national cancer research institute

Programme & Trade Exhibition Guide 2012

4–7 November 2012
BT Convention Centre, Liverpool, UK

Contents

SUNDAY 4 NOVEMBER

Programme at a Glance	2
-----------------------	---

MONDAY 5 NOVEMBER

Programme at a Glance	3
Symposia	6
Parallel Sessions	8
Proffered Paper Sessions	11
Workshops	13

TUESDAY 6 NOVEMBER

Programme at a Glance	16
Symposia	19
Parallel Sessions	21
Proffered Paper Sessions	24
Workshops	26

WEDNESDAY 7 NOVEMBER

Programme at a Glance	30
Parallel Sessions	32

Programme at a Glance SUNDAY

Welcome Address

15.00 – 15.10 Introduction from the Chair of the NCRI

Hall 1A **Professor Dame Janet Husband DBE**, Chair of the National Cancer Research Institute, UK

Plenary Lectures

Chaired by **Gerard Evan**, University of Cambridge, UK

15.10 – 15.50 Metastasis seeds and niches

Hall 1A **Joan Massagué**, Memorial Sloan-Kettering Cancer Center, New York, USA

15.50 – 16.30 Signal transduction pathways and Hsp 90 inhibitors: Latest

Hall 1A experiences and results from clinical trials (title TBC)

Neal Rosen, Memorial Sloan-Kettering Cancer Center, New York, USA



Refreshment Break

16.30 – 17.00 Refreshment break

Registration area & Galleria

Prize Awards

17.00 – 17.15 Cancer Research UK Prize ceremony

Hall 1A **Presented by Harpal Kumar**, Cancer Research UK, London, UK

Plenary Lecture

Chaired by **Nic Jones**, Chair of the Cancer Research UK Prizes Selection Panel

17.15 – 17.55 Cancer Research UK Lifetime Achievement in Cancer Research Prize winner

Hall 1A **Drugging the undruggable: How to finally tackle Myc, Ras, and p53**

David Lane, Agency for Science, Technology and Research, Singapore



Opening Reception and Trade Exhibition

18.00 – 20.00 For further details, please refer to the Trade Exhibition section in this book

Hall 2

Programme at a Glance MONDAY

3

Educational Workshop

08.00 – 08.45 **BACR Educational Workshop**

Room 11 **Pre-clinical breast cancer models**

Hosted by Valerie Speirs, Leeds Institute of Molecular Medicine, UK



Introduction to the Programme

08.50 – 09.00 **Message from the Chair of the 2012 Programme Committee**

Hall 1A **Patrick Johnston**, Queen's University Belfast, UK

Plenary Lectures

Chaired by Patrick Johnston, Queen's University Belfast, UK

09.00 – 09.40 **Targeting myeloma cells and their environment**

Hall 1A **Kenneth C. Anderson**, Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA

09.40 – 10.20 **Clinical cancer genetics in the era of personalised cancer medicine**

Hall 1A **Judy E. Garber**, Dana-Farber Cancer Institute, Boston, USA



Poster Session A (odd numbers), Refreshment Break and Trade Exhibition Viewing

10.20 – 11.00 **For further details, please refer to the Poster Abstracts book or USB stick,**

Hall 2 and the Trade Exhibition section in this book

Symposia

11.00 – 12.30 **Cancer in low and middle income countries - an increasing threat to development**
Room 3B

Hosted by Ian Magrath, International Network for Cancer Treatment and Research (INCTR), Brussels, Belgium

11.00 – 12.30 **Oncology drug development in 2012 - Challenges and opportunities of stratified patient populations**
Room 11

Hosted by Susan Galbraith, AstraZeneca, Macclesfield, UK

11.00 – 12.30 **Targeting cancer cells and promoting the immune effectors: From models to the clinic**
Room 3A

Hosted by Adrian Hayday, King's College London & Cancer Research UK London Research Institute, UK

11.00 – 12.30 **Understanding cancer as a microevolutionary process**

Hall 1A **Hosted by Gerard Evan**, University of Cambridge, UK

Lunch, Trade Exhibition Viewing and Poster Viewing

12.30 – 14.00 **For further details, please refer to the Poster Abstracts book or USB stick, and the Trade Exhibition section in this book**

Poster Session A (even numbers)

13.00 – 14.00 For further details, please refer to the Poster Abstracts book or USB stick
Hall 2

Proffered Paper Sessions

14.00 – 15.30 **Diagnosis and therapy**
Room 11 **Hosted by Richard Adams**, Velindre Cancer Centre, Cardiff, UK

14.00 – 15.30 **Early diagnosis, care delivery and quality of life**
Room 3A **Hosted by Peter Johnson**, Cancer Research UK, London, UK

14.00 – 15.30 **The cancer cell and model systems I**
Hall 1A **Hosted by Owen Sansom**, The Beatson Institute for Cancer Research, Glasgow, UK

Workshops

14.00 – 15.30 **Does an appreciation of the arts make us more empathic communicators?**
Room 4 **Hosted by Lesley Fallowfield**, SHORE-C, Brighton & Sussex Medical School, UK

14.00 – 15.30 **Tailoring biobanks for stratified medicine - cutting your tissue to fit**
Room 3B **Hosted by Daniel Glaser**, Wellcome Trust, London, UK



Poster Session A (odd numbers "replay"), Refreshment Break and Trade Exhibition Viewing

15.30 – 15.50 For further details, please refer to the Poster Abstracts book or USB stick,
Hall 2 and the Trade Exhibition section in this book

Parallel Sessions

15.50 – 17.20 **Cachexia – relationship with cancer treatment toxicity and update on drug and non-drug approaches**
Hall 1B

Hosted by Andrew Wilcock, The University of Nottingham, UK

15.50 – 17.20 **Cancer inequalities in the UK**
Room 3A **Hosted by Anna Gavin**, Northern Ireland Cancer Registry, UK

15.50 – 17.20 **Cold blooded cancer: Non-mammalian models for cancer research**
Room 4 **Hosted by Marcos Vidal**, The Beatson Institute for Cancer Research, Glasgow, UK

15.50 – 17.20 **Ovarian cancer: Turning knowledge into treatment**
Room 3B **Hosted by Iain McNeish**, Barts Cancer Institute, London, UK

15.50 – 17.20 **Paediatric oncology (CCLG session)**
Room 12 **Hosted by Josef Vormoor** on behalf of the Children's Cancer & Leukaemia Group (CCLG), Northern Institute for Cancer Research, Newcastle University, UK

15.50 – 17.20 **Predictive biomarker-driven phase II/III trials**
Room 11 **Hosted by Mahesh Parmar**, Medical Research Council Clinical Trials Unit, London, UK



15.50 – 17.20 **Rational approaches to combination of cancer therapies**

Hall 1A **Hosted by Ultan McDermott**, Wellcome Trust Sanger Institute, Cambridge, UK

15.50 – 17.20 **Surgery in the era of biomarkers and novel systematic and regional therapies**

Hall 1C **Hosted by Malcolm Dunlop**, University of Edinburgh & Western General Hospital, UK

Refreshment Break

17.20 – 17.40 Refreshment break

Hall 2

Plenary Lecture

Chaired by Irene Higginson, Cicely Saunders Institute, King's College London, UK

17.40 – 18.20 **Cancer pain control**

Hall 1A **Eduardo Bruera**, The University of Texas MD Anderson Cancer Center, USA

Plenary Lecture

Chaired by Chris Boshoff, University College London Cancer Institute, UK

18.20 – 19.00 **Targeting the CRKL/Src family kinases in rhabdomyosarcoma**

Hall 1A **Lee J. Helman**, National Cancer Institute, Bethesda, USA



Drinks Reception and Trade Exhibition viewing

19.00 – 21.15 **For further details, please refer to the Trade Exhibition section in this book**

Hall 2

Chair's Reception (*by invitation*)

20.00 – 22.30 Grace Suite, The Hilton Liverpool

Cancer in low and middle income countries - an increasing threat to development

- Room 3B **Hosted by Ian Magrath**, International Network for Cancer Treatment and Research (INCTR), Brussels, Belgium
- 11.00 – 11.15 **Introduction**
Ian Magrath, International Network for Cancer Treatment and Research (INCTR), Brussels, Belgium
- 11.15 – 11.40 **Descriptive epidemiology of cancer in developing countries and its importance to cancer control**
D. Maxwell Parkin, Clinical Trial Service Unit, University of Oxford & Cancer Registry Programme, International Network for Cancer Treatment and Research, Oxford, UK
- 11.40 – 12.05 **Recent advances in breast, cervix and oral cancer: Early detection and prevention in low and middle income countries**
Rengaswamy Sankaranarayanan, International Agency for Research on Cancer, World Health Organisation, Lyon, France
- 12.05 – 12.30 **Cancer control for India and the developing world**
Rajendra Badwe, Tata Memorial Centre, Mumbai, India

Oncology drug development in 2012 - Challenges and opportunities of stratified patient populations

- Room 11 **Hosted by Susan Galbraith**, AstraZeneca, Macclesfield, UK
- 11.00 – 11.15 **Introduction**
Susan Galbraith, AstraZeneca, Macclesfield, UK
- 11.15 – 11.40 **Translating pre-clinical hypotheses into the clinic – A tale of two kinases**
Nigel Brooks, AstraZeneca, Macclesfield, UK
- 11.40 – 12.05 **Developing novel anti-cancer therapies: Promises and challenges**
Jeff Evans, The Beatson Institute for Cancer Research, University of Glasgow & NHS Greater Glasgow and Clyde, Glasgow, UK
- 12.05 – 12.30 **Delivering on the promise of personalised medicine**
Gordon Mills, The University of Texas MD Anderson Cancer Center, Texas, USA

Targeting cancer cells and promoting the immune effectors: From models to the clinic

- Room 3A **Hosted by Adrian Hayday**, King's College London & Cancer Research UK London Research Institute, UK
- 11.00 – 11.15 **Introduction**
Adrian Hayday, King's College London & Cancer Research UK London Research Institute, UK
- 11.15 – 11.40 **Live imaging of the earliest inflammatory response to transformed cells within tissues - studies in zebrafish**
Paul Martin, University of Bristol, UK
- 11.40 – 12.05 **Peptide antigen characterisation for clinical immunotherapy studies**
Hans-Georg Rammensee, University of Tübingen, Germany
- 12.05 – 12.30 **PD-1 and LAG-3 in cancer immunotherapy**
Charles G. Drake, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA

Understanding cancer as a microevolutionary process

Hall 1A **Hosted by Gerard Evan**, University of Cambridge, UK

11.00 – 11.15 [Introduction](#)

Gerard Evan, University of Cambridge, UK

11.15 – 11.40 [Recent insights into the tempo and mode of somatic evolution](#)

Carlo Maley, The University of California, San Francisco, USA

11.40 – 12.05 [Evolutionary complexity in childhood acute lymphoblastic leukaemia](#)

Mel Greaves, The Institute of Cancer Research, London, UK

12.05 – 12.30 [Evolution of cancer genomes](#)

Peter Campbell, Wellcome Trust Sanger Institute, Cambridge, UK

KEY TO THEMES:

■ Diagnosis and therapy

■ Epidemiology and prevention

■ Information, patients and the public

■ Survivorship and end-of-life care

■ The cancer cell and model systems

■ Tumour-specific research

Cachexia – relationship with cancer treatment toxicity and update on drug and non-drug approaches

Hall 1B **Hosted by Andrew Wilcock**, The University of Nottingham, UK

15.50 – 16.05 Introduction

Andrew Wilcock, The University of Nottingham, UK

16.05 – 16.30 Role of cachexia in cancer treatment toxicity

Michael Sawyer, University of Alberta, Edmonton, Canada

16.30 – 16.55 Cancer cachexia: The molecular mechanisms

Josep M. Argilés, University of Barcelona, Spain

16.55 – 17.20 The role of therapeutic exercise in cancer cachexia

Matthew Maddocks, Cicely Saunders Institute, King's College London, UK

Cancer inequalities in the UK

Room 3A **Hosted by Anna Gavin**, Northern Ireland Cancer Registry, UK

15.50 – 16.05 Introduction

Anna Gavin, Northern Ireland Cancer Registry, UK

16.05 – 16.30 **Cancer inequalities and inequities in older people in the UK**

Tony Moran, North West Cancer Intelligence Service & The Christie NHS Foundation Trust, Manchester, UK

16.30 – 16.55 **Inequalities in cancer outcomes**

Michel Coleman, London School of Hygiene and Tropical Medicine, UK

16.55 – 17.20 **Cancer inequalities - a perspective from England**

Sir Mike Richards, National Cancer Director, National Cancer Action Team, London, UK



Cold blooded cancer: Non-mammalian models for cancer research

Room 4 **Hosted by Marcos Vidal**, The Beatson Institute for Cancer Research, Glasgow, UK

15.50 – 16.05 Introduction

Marcos Vidal, The Beatson Institute for Cancer Research, Glasgow, UK

16.05 – 16.30 **Anchor cell invasion in *C. elegans* - Cell cycle progression antagonises invasion**

David Sherwood, Duke University, Durham, USA

16.30 – 16.55 **Intestinal stem cell control in the healthy and hyperplastic *Drosophila* gut**

Bruce Edgar, DKFZ-ZMBH Alliance, Heidelberg, Germany

16.55 – 17.20 **Novel determinants of melanoma progression from zebrafish**

Adam Hurlstone, The University of Manchester, UK

Ovarian cancer: Turning knowledge into treatment



- Room 3B **Hosted by Iain McNeish**, Barts Cancer Institute, London, UK
- 15.50 – 16.05 **Introduction**
Iain McNeish, Barts Cancer Institute, London, UK
- 16.05 – 16.30 **Ovarian cancer screening - the future**
Usha Menon, University College London, UK
- 16.30 – 16.55 **Genomics and the personalisation of ovarian cancer care**
David Huntsman, BC Cancer Agency, Vancouver, Canada
- 16.55 – 17.20 **Clinical implications of intratumoural heterogeneity on high-grade serous ovarian cancer**
James Brenton, Cancer Research UK Cambridge Research Institute, UK

Paediatric oncology (CCLG session)

- Room 12 **Hosted by Josef Vormoor** on behalf of the Children's Cancer & Leukaemia Group (CCLG), Northern Institute for Cancer Research, Newcastle University, UK
- 15.50 – 16.05 **Winner of the 2012 CCLG McElwain Prize: Dissecting the clonal architecture of paediatric leukaemia**
Nicola Potter, The Institute of Cancer Research, London, UK
- 16.05 – 16.30 **Distinct biological drivers of high grade glioma in children and young adults**
Lynn Bjerke, The Institute of Cancer Research, London, UK
- 16.30 – 16.55 **Immunotherapeutic approaches in childhood high grade glioma**
John Anderson, University College London & Institute of Child Health, Great Ormond Street Hospital, UK
- 16.55 – 17.20 **Challenges of introducing biologically targeted therapy in paediatric high grade glioma**
Darren Hargrave, Great Ormond Street Hospital, London, UK

Predictive biomarker-driven phase II/III trials

- Room 11 **Hosted by Mahesh Parmar**, Medical Research Council Clinical Trials Unit, London, UK
- 15.50 – 16.05 **Introduction**
Mahesh Parmar, Medical Research Council Clinical Trials Unit, London, UK
- 16.05 – 16.30 **The development and validation of predictive biomarkers for phase II/III studies**
Richard Kennedy, Queen's University Belfast, UK
- 16.30 – 16.55 **Predictive biomarker trials in breast cancer**
Jo Anne Zujewski, National Cancer Institute, Bethesda, USA
- 16.55 – 17.20 **The design of FOCUS 4: A molecularly-stratified, multi-arm multistaged (MAMS) randomised controlled trial phase II/III programme in advanced colorectal cancer (ACRC)**
Timothy Maughan, University of Oxford, UK



Rational approaches to combination of cancer therapies

- Hall 1A **Hosted by Ultan McDermott**, Wellcome Trust Sanger Institute, Cambridge, UK
- 15.50 – 16.05 **Introduction**
Ultan McDermott, Wellcome Trust Sanger Institute, Cambridge, UK
- 16.05 – 16.30 **Targeting unique dependencies of RAS mutant tumours by combined pathway inhibition**
Julian Downward, Cancer Research UK London Research Institute, UK

- 16.30 – 16.55 **The application of genetic screens and principles to the design of drug combination strategies**
Christopher Lord, The Institute of Cancer Research, London, UK
- 16.55 – 17.20 **Complex molecular interactions as determinants of disease outcome and therapy response**
Lodewyk Wessels, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Surgery in the era of biomarkers and novel systematic and regional therapies

- Hall 1C **Hosted by Malcolm Dunlop**, University of Edinburgh & Western General Hospital, UK
- 15.50 – 16.05 **Introduction**
Malcolm Dunlop, University of Edinburgh & Western General Hospital, UK
- 16.05 – 16.30 **The implications of clonal genome evolution for cancer medicine**
Sam Aparicio, BC Cancer Agency Research Centre, Vancouver, Canada
- 16.30 – 16.55 **The search for biomarkers in prostate cancer**
Freddie Hamdy, University of Oxford, UK
- 16.55 – 17.20 **Pancreas cancer genetics and the surgeon - should you care?**
Steven Gallinger, University of Toronto, Canada

Diagnosis and therapy

- Room 11 **Hosted by Richard Adams**, Velindre Cancer Centre, Cardiff, UK
- 14.00 – 14.10 **Seven year follow-up of the Medical Research Council CLASICC trial of laparoscopically assisted versus open surgery for colorectal cancer**
Ben Green, University of Leeds, UK
- 14.10 – 14.20 **EPOC Trial: EORTC liver metastases intergroup randomised phase III study 40983 - Long-term survival results**
John Primrose, University of Southampton, UK
- 14.20 – 14.30 **HiLo: Multicentre randomised phase III clinical trial of high vs. low dose radioiodine, with or without recombinant human thyroid stimulating hormone (rhTSH), for remnant ablation for differentiated thyroid cancer (DTC)**
Allan Hackshaw, University College London, UK
- 14.30 – 14.40 **Results of KRAS/BRAF/NRAS all-wild-type outcome analysis in the MRC COIN-B randomised trial in patients with advanced colorectal cancer**
Harpreet Wasan, Imperial College Healthcare NHS Trust, London, UK
- 14.40 – 14.50 **Identification of reprogramming of the kinome following vemurafenib treatment in BRAF mutant colorectal cancer cells**
Robbie Carson, Queen's University Belfast, UK
- 14.50 – 15.00 **Tyrosine phosphatase inhibitors combine with retinoic acid to enhance neuroblastoma cell differentiation and trigger ERK- and AKT-dependent, p53-independent senescence**
Andrew Stoker, Institute of Child Health, University College London, UK
- 15.00 – 15.10 **Identification of 23 novel prostate cancer susceptibility loci using a custom array (the iCOGS) in an international consortium, PRACTICAL**
Chee Goh, The Institute of Cancer Research, London, UK
- 15.10 – 15.20 **Performance characteristics of multimodal screening with serum CA125 in the United Kingdom collaborative trial of ovarian cancer screening (UKCTOCS)**
Ian Jacobs, University College London Elizabeth Garrett Anderson Institute for Women's Health, London & The University of Manchester, UK
- 15.20 – 15.30 **Discussion**

Early diagnosis, care delivery and quality of life

- Room 3A **Hosted by Peter Johnson**, Cancer Research UK, London, UK
- 14.00 – 14.10 **Epidemiology and molecular pathology of the first 1000 participants in the Cancer Research UK Stratified Medicine Programme**
Emily Shaw, Cancer Research UK, London, UK
- 14.10 – 14.20 **Breast cancer diagnosis and treatment in women aged 18-40 years in the UK: Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH)**
Bryony Eccles, University of Southampton, UK

- 14.20 – 14.30 **Identification of men with a genetic predisposition to prostate cancer - Targeted screening of BRCA1/2 mutation carriers and controls: The IMPACT study**
Elizabeth Page, The Institute of Cancer Research, London, UK
- 14.30 – 14.40 **Community cancer treatment: Final results of the Outreach randomised clinical trial**
Pippa Corrie, Addenbrooke's Hospital, Cambridge, UK
- 14.40 – 14.50 **Supportive care in cancer: Findings from the 2010 National Cancer Patient Experience Survey in England**
Fiona Mendes, North Wales Centre for Primary Care Research, North Wales Clinical School, Wrexham, UK
- 14.50 -15.00 **A comparison of clinician- versus patient-reported outcomes (PROMS) for late normal tissue side-effects following breast radiotherapy: Results of the Cambridge Breast Intensity Modulated Radiotherapy Trial (IMRT) Trial**
Charleen Chan Wah Hak, University of Cambridge, UK
- 15.00 – 15.10 **Measuring quality of life for QALY estimation with cyclical cancer therapies**
Felicity Roussak, University of Leeds, UK
- 15.10 – 15.20 **Gleason upgrading with time in a large, active surveillance cohort with long-term follow-up**
Suneil Jain, Sunnybrook Odette Cancer Centre, Toronto, Canada
- 15.20 – 15.30 **Discussion**

The cancer cell and model systems I

- Hall 1A **Hosted by Owen Sansom**, The Beatson Institute for Cancer Research, Glasgow, UK
- 14.00 – 14.15 **AstraZeneca Student Prize Award: Identification of metabolic genes essential for proliferation of clear cell renal cell carcinoma (ccRCC) cells**
Heike Miess, Cancer Research UK London Research Institute, UK
- 14.15 – 14.30 **ACP McElwain Prize: The preclinical and clinical development of AKT inhibitors and associated biomarkers**
Timothy A. Yap, The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust, London, UK
- 14.30 – 14.40 **Association of ALK^{F1174L} expression with altered vasculature in transgenic murine models of neuroblastoma**
Laura Glass, The Institute of Cancer Research, London, UK
- 14.40 – 14.50 **Propagation of epithelial polarity through mitosis**
Graham Bell, Cancer Research UK & University College London, UK
- 14.50 – 15.00 **The c-MET-JAK1/2-STAT3 signalling axis is a critical mediator of drug resistance in Kras mutant colorectal cancer**
Sandra Van Schaeybroeck, Queen's University Belfast, UK
- 15.00 – 15.10 **Colorectal tumour microRNAs - novel biomarkers of tumour progression and treatment response?**
Edward Amankwatia, University of Dundee, UK
- 15.10 – 15.20 **Inhibition of Ras-dependent cellular transformation and tumourigenesis by transcription factor, ATF2**
Malgorzata Grozdecka, Paterson Institute for Cancer Research, Manchester, UK
- 15.20 – 15.30 **Discussion**

BACR Educational Workshop

Pre-clinical breast cancer models

Hosted by Valerie Speirs, Leeds Institute of Molecular Medicine, UK

08.00 – 08.45, Room 11



Breast cancer is a complex and heterogeneous disease. Such heterogeneity has been recognised further with breast cancer now classified into at least 10 molecular subtypes¹. In addition, the recognition that the breast microenvironment plays an active role in dictating mammary epithelial cell behaviour calls for a need for models which better define the *in vivo* environment to use in breast cancer research. Given that breast cancer is so diverse one single model is unlikely to recapitulate all aspects of breast cancer progression. This workshop will outline the pros and cons of different types of breast cancer models, from simple 2D to more complex 3D *in vitro* models, through to animal models to study metastasis. Their suitability to address different biological questions will be discussed.

1. Curtis C et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. *Nature* 2012; Apr 18. doi: 10.1038/nature10983.

Speakers:

Breast cancer metastasis - how do we choose the right *in vivo* model?

Ingunn Holen, University of Sheffield, UK

In vivo models remain a key part of the cancer researcher's toolkit, generating valuable data that provide new insights into mechanisms of cancer progression and response to therapy. The models are particularly valuable for studies of metastatic disease, a complex process that cannot be adequately mimicked *in vitro*. Increasingly, researchers find that some evidence of function or efficacy from *in vivo* models is required in order to publish their findings in high impact journals. Choosing the right model(s) to answer a specific research question is of great importance, and requires a clear understanding of the strengths and limitations of a particular model. Some models are suited to studies of the early stages of tumour growth and initiation of metastasis, others to investigate growth in particular organ sites. No single model will be a perfect representation of human tumour metastasis, and careful interpretation of the resulting data is essential. With emphasis on bone metastasis, I will show some examples of novel insights into breast cancer obtained from *in vivo* models, and highlight the strengths and weaknesses of the approach.

3D *in vitro* model systems of breast cancer: Where are we now and where are we going?

J. Louise Jones, Barts Cancer Institute, London, UK

A major challenge for any *in vitro* model system is to achieve physiological relevance. In this respect, moving from the traditional 2D monolayer cell culture system to the 3D environment has been a significant advance, allowing the roles of dimensionality, extracellular matrix and cell-cell interactions to be taken into account. Some of the first 3D systems were described by the labs of Brugge¹ and Bissell², who used overlay of breast epithelial cells with reconstituted basement membrane to generate a 3D culture, and showed that moving from 2D to 3D alone influences cell differentiation, growth kinetics and metabolic rate. Since these groundbreaking studies, systems of greater complexity have been developed that have allowed modelling of the interactions between different cell populations³, different matrices and mechanical forces⁴. These models typically involve formation of a matrix 'gel' within which the cells are embedded, either as single cells or as preformed multicellular units. The advantage of such systems is the relative complexity that begins to mirror the *in vivo* environment, but challenges include variability between cultures, the large number of cells required and limitations in quantification. Some of these limitations can be addressed using organotypic culture systems, such as improved quantitation of processes such as invasion, but reproducibility remains an issue.

An engineered poly(dimethylsiloxane) (PDMS) microwell array system has been developed for the standardised screening of tumour response to drug treatments⁵. This system allows culture of cells in a 3D environment where both control of cell cluster size and protein coating can be controlled independently. This system has the advantage of high reproducibility, but arguably at the expense of complexity.

A further disadvantage of conventional 3D model systems is that they are labour intensive and require large numbers of cells. Microfluidic approaches offer opportunities for significant scalability and automation, with real potential for high-throughput screening. These systems have recently been applied to multicellular co-culture models of DCIS6, so combining complexity with efficiency, and mark an exciting development in the field of bioengineering.

1. Debnath J, Muthuswamy SK, Brugge JS (2003). *Methods* 30: 256-268.
2. Schmeichel KL, Bissell MJ. (2003). *J Cell Sci.* 116: 2377-2388.
3. Holliday DL, Brouillette KT, Markert A, et al. (2009). *Br. Cancer Res.* 11: R3.
4. Hakanson M, Textor M, Charnley M (2011). *Integrative Biology* 3: 31-38.
5. Sung KE, Su G, Pehlke C. et al. (2009). *Biomaterials* 30:4833-41.
6. Sung KE, Yang N, Pehlke C. et al. (2011). *Integrative Biology* 3: 439-450.

Afternoon Workshops

Does an appreciation of the arts make us more empathic communicators?

Hosted by Lesley Fallowfield, SHORE-C, Brighton & Sussex Medical School, UK

14.00 – 15.30, Room 4

Emotional burnout in oncologists is high. Many seek solace in ways unlikely to improve psychological well-being and that damage relationships with patients and professional colleagues.

This session should increase awareness of the role of the arts in helping patients, carers and healthcare professionals articulate the powerful emotions experienced in an oncology setting.

White coat and purple coat: The writings and influence of Dr Dannie Abse (poet, playwright and physician)

Irene Higginson, Cicely Saunders Institute, King's College London, UK

'The Emotional Cancer Journey'

DVD of the paintings and writings of Michele Angelo Petrone, an Italian painter who died of Hodgkin's Disease. The background music (Spiegel Im Spiegel by Arvo Part) is played by Tamsin Little, the voice of Michele Petrone - William Gaminara

Tailoring biobanks for stratified medicine - cutting your tissue to fit

Hosted by Daniel Glaser, Wellcome Trust, London, UK

14.00 – 15.30, Room 3B

Science never stands still. One of the challenges of tissue banking for research is to future proof our resources. Tissue Bankers need to keep abreast of new technologies and new guidelines for reporting scientific studies to ensure that the material that they collect from patients now is useful for science in the future. This workshop looks at three key areas – ensuring that samples come with sufficient annotation and quality standards for results obtained from them to be published in the most highly rated journals; how collection strategies can be developed to ensure that we have the right samples from patients to answer relevant clinical questions in the future; and how new technologies and animal models for research using clinical material have great potential in directing treatment strategies for both the patients of today and tomorrow.

The workshop is chaired by Daniel Glaser, who is Head of Special Projects for Public Engagement at the Wellcome Trust.

Following talks by our three speakers, there will be a discussion on the issues raised. Come and help us provide you with what you need for your future research.

Alison Parry-Jones, Wales Cancer Bank, Cardiff, UK



Speakers:

15

Quality of science on human material – is it improving?

Doug Altman, University of Oxford, UK

Metastatic biobanking

Noel Clarke, The University of Manchester, UK

Human tissue in animal models

Speaker TBC

Educational Workshop

- 08.00 – 08.45 **BACR Educational Workshop**
Room 11 **Translation of radiation biology into meaningful clinical trials: All aboard!**
Hosted by Ricky Sharma, University of Oxford, UK



Plenary Lectures

Chaired by Jane Barrett, President of The Royal College of Radiologists, UK

- 09.00 – 09.25 **The breast screening review**
Hall 1A **Harpal Kumar**, Cancer Research UK, London, UK
- 09.25 – 09.50 **The breast screening review: Evidence and recommendations**
Hall 1A **Sir Michael Marmot**, Institute of Health Equity, University College London, UK
- 09.50 – 10.20 **Q&A session**



Poster Session B (odd numbers), Refreshment Break and Trade Exhibition Viewing

- 10.20 – 11.00 **For further details, please refer to the Poster Abstracts book or USB stick, and the Trade Exhibition section in this book**
Hall 2

Educational Workshop

- 11.00 – 15.00 **Cutting edge translational research in head and neck cancer**
Room 4 **Hosted by Hisham Mehanna**, Institute of Head and Neck Studies and Education, Coventry, UK

Symposia

- 11.00 – 12.30 **Improvements in palliative and supportive care: Recent advances**
Room 3A **Hosted by Irene Higginson**, Cicely Saunders Institute, King's College London, UK
- 11.00 – 12.30 **Lung cancer - state of the art and science**
Room 3B **Hosted by Fergus Macbeth**, Wales Cancer Trials Unit, Cardiff, UK
- 11.00 – 12.30 **Tumour-environment interactions**
Hall 1A **Hosted by Margaret Frame**, Edinburgh Cancer Research Centre, UK
- 11.00 – 12.30 **Where next with genome-wide association studies?**
Room 11 **Hosted by Bruce Ponder**, Cancer Research UK Cambridge Research Institute, UK



Lunch, Trade Exhibition Viewing and Poster Viewing

- 12.30 – 14.00 **For further details, please refer to the Poster Abstracts book or USB stick, and the Trade Exhibition section in this book**
Hall 2



Commercial Workshop

- 13.00 – 14.00 **Headlines of International Conferences in 2012**
 Room 11 **Sponsored by Roche Products Limited**

Poster Session B (even numbers)

- 13.00 – 14.00 **For further details, please refer to the Poster Abstracts book or USB stick, and the Trade Exhibition section in this book**
 Hall 2

Proffered Paper Sessions

- 14.00 – 15.30 **Cancer awareness, early diagnosis and care**
 Room 3A **Hosted by Richard Neal, Bangor University, UK**
- 14.00 – 15.30 **Radiotherapy and radiobiology**
 Room 11 **Hosted by Adrian Crellin, St. James's Institute of Oncology, Leeds, UK & Vice President, The Royal College of Radiologists, UK**
- 14.00 – 15.30 **The cancer cell and model systems II**
 Hall 1A **Hosted by Caroline Dive, Paterson Institute for Cancer Research, Manchester, UK**

Workshops

- 14.00 – 15.30 **Improving the management of cerebral metastatic disease**
 Room 12 **Hosted by NCRI Brain Tumour Clinical Studies Group, UK**
- 14.00 – 15.30 **Transforming oncology research: New models for novel therapeutic approaches**
 Room 3B **Hosted by French National Cancer Institute (INCa), France**



Poster Session B (odd numbers "replay"), Refreshment Break and Trade Exhibition Viewing

- 15.30 – 15.50 **For further details, please refer to the Poster Abstracts book or USB stick, and the Trade Exhibition section in this book**
 Hall 2

Parallel Sessions

- 15.50 – 17.20 **Acute oncology**
 Room 3A **Hosted by Diana Tait, The Royal College of Radiologists, UK**
- 15.50 – 17.20 **Advances in the biology and management of liver malignancy**
 Hall 1B **Hosted by John Primrose, University of Southampton & Southampton General Hospital, UK**
- 15.50 – 17.20 **Cell death, necroptosis and beyond**
 Room 4 **Hosted by Henning Walczak, Imperial College London, UK**
- 15.50 – 17.20 **Human factors in early diagnosis**
 Hall 1C **Hosted by Jane Wardle, University College London, UK**



- 15.50 – 17.20 **Mechanisms of drug resistance**
Hall 1A **Hosted by Julian Downward**, Cancer Research UK London Research Institute, UK
- 15.50 – 17.20 **Patients, participants and public – Different perspectives, shared views?**
Room 12 **Hosted by Richard Stephens**, NCRI Consumer Liaison Group, UK
- 15.50 – 17.20 **Primary and secondary cancer prevention – lifestyle interventions**
Room 3B **Hosted by Annie Anderson**, University of Dundee, UK
- 15.50 – 17.20 **Stem cells, heterogeneity and clonal evolution in cancer**
Room 11 **Hosted by Tariq Enver**, University College London Cancer Institute, UK

Refreshment Break

- 17.20 – 17.40 **Refreshment break**
Hall 2

Clinical Trials Showcase

Chaired by Matt Seymour, National Cancer Research Network, Leeds, UK



- 17.40 – 18.00 **Final analysis of intergroup randomised phase III study of androgen deprivation therapy (ADT) + radiation therapy (RT) in locally advanced prostate cancer (CaP) (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110)**
Hall 1A
Malcolm Mason, Cardiff University, UK
- 18.00 – 18.20 **The pattern and timing of disease recurrence in squamous cancer of the anus: Mature results from the NCRI ACT II trial**
Hall 1A
David Sebag-Montefiore, St James's Institute of Oncology, University of Leeds, UK
- 18.20 – 18.40 **Treatment of advanced neuroendocrine tumours: Final results of the UKI NETS and NCRI randomised phase 2 NET 01 trial**
Hall 1A
Pippa Corrie, Addenbrooke's Hospital, Cambridge, UK
- 18.40 – 19.00 **Phase III multi-centre, randomised, double-blind, placebo-controlled trial of gefitinib versus placebo in oesophageal cancer progressing after chemotherapy, COG (Cancer Oesophagus Gefitinib)**
Hall 1A
David R. Ferry, Russells Hall Hospital, Dudley, UK

Quality in Care Oncology Programme Awards (*by invitation*)

- 19.30 – 22.00 Grace Suite, The Hilton Liverpool

Conference dinner and party (*ticketed event*)

- 20.00 onwards The Marquee, BT Convention Centre

Improvements in palliative and supportive care

Room 3A **Hosted by Irene Higginson**, Cicely Saunders Institute, King's College London, UK

11.00 – 11.15 **Introduction**

Irene Higginson, Cicely Saunders Institute, King's College London, UK

11.15 – 11.40 **Advances, challenges and opportunities in symptom management in older patients with cancer**

Deborah Dudgeon, Queen's University, Ontario, Canada

11.40 – 12.05 **Recent advances in developing a national end-of-life care register**

Carl Johan Fürst, Karolinska Institutet & Stockholms Sjukhem Foundation, Stockholm, Sweden

12.05 – 12.30 **Recent advances in the detection and management of psychological distress and depression in cancer and palliative care**

Mari Lloyd-Williams, University of Liverpool, UK



Lung cancer - state of the art and science

Room 3B **Hosted by Fergus Macbeth**, Wales Cancer Trials Unit, Cardiff, UK

11.00 – 11.15 **Introduction**

Fergus Macbeth, Wales Cancer Trials Unit, Cardiff, UK

11.15 – 11.40 **The 2012 George Edelstyn Lecture: The application of translational science in non-small cell lung cancer (NSCLC): Successes, failures and pitfalls**

Frances Shepherd, University of Toronto and Princess Margaret Hospital, Ontario, Canada

11.40 – 12.05 **Lung Stereotactic Ablative Radiotherapy (SABR): The state of the art**

Kevin Franks, St James's Institute of Oncology, Leeds, UK

12.05 – 12.30 **Radical radiotherapy for locally advanced NSCLC - Current research and controversies**

Corinne Faivre-Finn, The Christie NHS Foundation Trust, Manchester, UK



Tumour-environment interactions

Hall 1A **Hosted by Margaret Frame**, Edinburgh Cancer Research Centre, UK

11.00 – 11.15 **Introduction**

Margaret Frame, Edinburgh Cancer Research Centre, UK

11.15 – 11.40 **Tumour:stroma interactions in breast cancer metastasis**

Clare Isacke, The Institute of Cancer Research, London, UK

11.40 – 12.05 **Prognostic, predictive and therapeutic potential of PDGFR - positive cancer-associated fibroblasts**

Arne Östman, Karolinska Institutet, Stockholm, Sweden

12.05 – 12.30 **Intravital microscopy of tumour cells and their microenvironment through imaging windows**

Jacco van Rheenen, Hubrecht Institute, Utrecht, The Netherlands

Where next with genome-wide association studies?

20

- Room 11 **Hosted by Bruce Ponder**, Cancer Research UK Cambridge Research Institute, UK
- 11.00 – 11.15 **Introduction**
Bruce Ponder, Cancer Research UK Cambridge Research Institute, UK
- 11.15 – 11.40 **Polygenic risk prediction: The clinical significance**
Paul Pharoah, University of Cambridge, UK
- 11.40 – 12.05 **Unexplained familial breast cancer risk - how can we find the missing genes?**
Julian Peto, London School of Hygiene and Tropical Medicine, UK
- 12.05 – 12.30 **Interrogating regulatory networks to elucidate drivers of tumourigenesis, progression, and drug sensitivity**
Andrea Califano, Columbia University, New York, USA

KEY TO THEMES:

■ Diagnosis and therapy

■ Epidemiology and prevention

■ Information, patients and the public

■ Survivorship and end-of-life care

■ The cancer cell and model systems

■ Tumour-specific research

Acute oncology

Room 3A **Hosted by Diana Tait**, The Royal College of Radiologists, UK

15.50 – 16.10 **The impact of acute oncology services on the management of malignant spinal cord compression (MSCC) in the UK: Early results of the Royal College of Radiologists' re-audit**

Imogen Locke, The Royal Marsden NHS Foundation Trust, London, UK

16.10 – 16.30 **Unknown primary team, pathways and outcomes**

Gillian Knowles, NHS Lothian, Edinburgh, UK

16.30 – 16.50 **Development of an oncology assessment area at the Edinburgh Cancer Centre**

Fiona Nussey, NHS Lothian, Edinburgh, UK

16.50 – 17.10 **Acute oncology - Models of delivery**

Brian Haylock, Clatterbridge Cancer Centre, Wirral, UK

17.10 – 17.20 **COAST-II: Development of a programme for equivalence assessment in IMRT treatment planning**

Rajesh Jena, Cambridge University Hospitals NHS Foundation Trust, UK



Advances in the biology and treatment of liver malignancy

Hall 1B **Hosted by John Primrose**, University of Southampton & Southampton General Hospital, UK

15.50 – 16.05 **Introduction**

John Primrose, University of Southampton & Southampton General Hospital, UK

16.05 – 16.30 **Management of hepatocellular carcinoma**

Jean-Francois Dufour, University of Berne, Switzerland

16.30 – 16.55 **Biliary tract cancer: Progress and challenges**

John Bridgewater, University College London Cancer Institute, UK

16.55 – 17.20 **Colorectal liver metastases**

John Primrose, University of Southampton & Southampton General Hospital, UK

Cell death, necroptosis and beyond

Room 4 **Hosted by Henning Walczak**, Imperial College London, UK

15.50 – 16.05 **Introduction**

Henning Walczak, Imperial College London, UK

- 16.05 – 16.30 **Role of RIPK1 and RIPK3 in cell death modality switches**
Peter Vandenabeele, Flanders Institute for Biotechnology (VIB) & Ghent University (UGent), Belgium
- 16.30 – 16.55 **IAPs: From caspase inhibitors to modulators of NF- κ B, inflammation and cancer**
Pascal Meier, The Institute of Cancer Research, London, UK
- 16.55 – 17.20 **Cutting both ways: How caspases promote and prevent cell death**
Douglas Green, St. Jude Children's Research Hospital, Memphis, USA

Human factors in early diagnosis



- Hall 1C **Hosted by Jane Wardle**, University College London, UK
- 15.50 – 16.05 **Introduction**
Jane Wardle, University College London, UK
- 16.05 – 16.30 **Public knowledge and attitudes towards early diagnosis**
Jane Wardle, University College London, UK
- 16.30 – 16.55 **Increasing early detection of symptomatic lung cancer - results of a combined marketing communications campaign and primary care education programme in Leeds, UK**
Matthew Callister, St. James's University Hospital, Leeds, UK
- 16.55 – 17.20 **The use and misuse of numeric information about health risks**
Mirta Galesic, Max Planck Institute for Human Development, Berlin, Germany

Mechanisms of drug resistance

- Hall 1A **Hosted by Julian Downward**, Cancer Research UK London Research Institute, UK
- 15.50 – 16.05 **Introduction**
Julian Downward, Cancer Research UK London Research Institute, UK
- 16.05 – 16.30 **Challenges in overcoming resistance to targeted therapies**
Jeffrey Engelman, Massachusetts General Hospital, USA
- 16.30 – 16.55 **Resistance to PARP inhibition in mouse models of BRCA1-deficient breast cancer**
Sven Rottenberg, The Netherlands Cancer Institute, Amsterdam, The Netherlands
- 16.55 – 17.20 **Mechanisms of estrogen receptor transcription in breast cancer**
Jason Carroll, Cancer Research UK Cambridge Research Institute, UK

Patients, participants and public – Different perspectives, shared views?

- Room 12 **Hosted by Richard Stephens**, NCRI Consumer Liaison Group, UK
- 15.50 – 15.55 **Introduction**
Richard Stephens, NCRI Consumer Liaison Group, UK
- 15.55 – 16.15 **Cancer research - a positive response from patients**
Carolyn Morris, NCRI Consumer Liaison Group, UK
- 16.15 – 16.35 **The National Cancer Patient Experience Survey**
Reg Race, Quality Health, UK
- 16.35 – 16.55 **From RAGs to riches - Taking public and patient involvement from the high street to the bedside**
Ian Lewis, Tenovus, Cardiff, UK
- 16.55 – 17.15 **Q&A**
- 17.15 – 17.20 **Summary**

Primary and secondary cancer prevention – lifestyle interventions

- Room 3B **Hosted by Annie Anderson**, University of Dundee, UK
- 15.50 – 16.05 **Introduction**
Annie Anderson, University of Dundee, UK
- 16.05 – 16.30 **Weight management in breast cancer - a primary prevention challenge?**
Michelle Harvie, Genesis Prevention Centre, University Hospital South Manchester, UK
- 16.30 – 16.55 **Lifestyle change in cancer survivors...do we wait for trial evidence?**
Wendy Demark-Wahnefried, University of Alabama at Birmingham, USA
- 16.55 – 17.20 **The importance of physical activity for cancer survivors: Current evidence and ongoing research**
Johannes Brug, VU University Medical Centre, Amsterdam, The Netherlands

Stem cells, heterogeneity and clonal evolution in cancer

- Room 11 **Hosted by Tariq Enver**, University College London Cancer Institute, UK
- 15.50 – 16.05 **Introduction**
Tariq Enver, University College London Cancer Institute, UK
- 16.05 – 16.30 **Mechanisms regulating cutaneous cancer stem cells**
Cedric Blanpain, Université Libre de Bruxelles & IRIBHM-WELBIO, Brussels, Belgium
- 16.30 – 16.55 **Cancer stem cells from human brain tumours**
Peter Dirks, The Hospital for Sick Children, Toronto, Canada
- 16.55 – 17.20 **Clonal evolution and intratumour heterogeneity**
Charlie Swanton, University College London Cancer Institute, UK

Cancer awareness, early diagnosis and care

- Room 3A **Hosted by Richard Neal**, Bangor University, UK
- 14.00 – 14.10 **Population based testing for inherited cancer predisposing BRCA1/2 mutations is acceptable and detects at risk carriers without a strong family history of cancer**
Ian Jacobs, The University of Manchester & University College London Elizabeth Garrett Anderson Institute for Women's Health, UK
- 14.10 – 14.20 **Perceptions of the English NHS Bowel Cancer Screening Programme information materials: A Think-Aloud Study**
Samuel G. Smith, University College London, UK
- 14.20 – 14.30 **The association between the number of general practitioner consultations before hospital referral for cancer and primary care interval ('delay'): Data from the English National Audit of Cancer Diagnosis in Primary Care**
Georgios Lyratzopoulos, University of Cambridge, UK
- 14.30 – 14.40 **Survival from teenage and young adult cancer in the North of England, 1968 - 2005**
Nermine Basta, Newcastle University, UK
- 14.40 – 14.50 **Let's Talk About It: Evaluation of a school-based cancer awareness education programme delivered by Teenage Cancer Trust in the UK**
Amy Harding, Teenage Cancer Trust, London, UK
- 14.50 – 15.00 **Experience of breathlessness and pain by post surgical lung cancer survivors during the first post operative year: A qualitative study**
Amanda Farley, University of Birmingham, UK
- 15.00 – 15.10 **Factors associated with low health-related quality-of-life in colorectal cancer survivors: The importance of family, socio-economic and financial circumstances**
Linda Sharp, National Cancer Registry Ireland, UK
- 15.10 – 15.20 **Change in commonly recorded clinical parameters in the final two weeks of life**
Paul Taylor, Hull and York Medical School, UK
- 15.20 – 15.30 **Discussion**

Radiotherapy and radiobiology

- Room 11 **Hosted by Adrian Crellin**, St. James's Institute of Oncology & Vice President, The Royal College of Radiologists, UK
- 14.00 – 14.10 ***In vivo* imaging of DNA damage response during tumourigenesis**
Bart Cornelissen, University of Oxford, UK
- 14.10 – 14.20 **Optimisation and individualisation of Heart-Sparing Breast Radiotherapy Techniques (The HeartSpare Study)**
Frederick Bartlett, The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust, London, UK
- 14.20 – 14.30 **Targeting radiation-resistant hypoxic tumour cells through ATR inhibition**
Ester Hammond, Gray Institute for Radiation Oncology and Biology, University of Oxford, UK
- 14.30 – 14.40 **AEG-1 expression is related to radiation response in rectal cancer patients from a clinical trial of preoperative radiotherapy and in cancer cell lines**
Sebastian Gnosa, University of Linköping, Sweden
- 14.40 – 14.50 **¹¹¹In-bnDTPA-bevacizumab for imaging VEGF and assessing response to rapamycin therapy**
Neel Patel, University of Oxford, UK

- 14.50 – 15.00 [Quality of life \(QOL\) and updated survival and safety data of radium-223 chloride \(Ra-223\) in patients with castration-resistant prostate cancer \(CRPC\) with bone metastases from the phase 3 ALSYMPCA study](#)
Christopher Parker, The Royal Marsden NHS Foundation Trust, London, UK
- 15.00 – 15.10 [p16^{INK4A} predicts outcome following chemo-radiotherapy in squamous cell cancers of the anus](#)
Duncan Gilbert, Royal Sussex County Hospital & Brighton and Sussex Medical School, UK
- 15.10 – 15.20 [Liver stereotactic body radiation therapy \(SBRT\) for treatment refractory metastatic liver disease](#)
Katharine Aitken, The Royal Marsden NHS Foundation Trust, London, UK
- 15.20 – 15.30 **Discussion**

The cancer cell and model systems II

- Hall 1A **Hosted by Caroline Dive**, Paterson Institute for Cancer Research, Manchester, UK
- 14.00 – 14.15 [BACR Frank Rose Award: Metastasis driven by the tumour microenvironment](#)
Janine T. Erler, University of Copenhagen, Denmark
- 14.15 – 14.30 [BACR Translational Research Award: Characterisation of expressed fusion genes in micropapillary carcinomas of the breast](#)
Rachael Natrajan, The Institute of Cancer Research, London, UK
- 14.30 – 14.40 [RASSF1A loss deregulates hippo pathway signalling in tumourigenesis](#)
Angelos Papaspyropoulos, University of Oxford, UK
- 14.40 – 14.50 [Mechanisms of DNA replication initiation](#)
Thomas Deegan, Cancer Research UK, Clare Hall Laboratories, Potters Bar, UK
- 14.50 – 15.00 [Contrasting effects of sunitinib within *in vivo* models of metastasis](#)
Andrew Reynolds, The Institute of Cancer Research, London, UK
- 15.00 – 15.10 [The receptor tyrosine kinase EpHA2 is a poor prognostic marker and a novel target in Kras mutant colorectal cancer](#)
Philip Dunne, Queen's University Belfast, UK
- 15.10 – 15.20 [Induced pluripotent stem cell \(iPSC\) reprogramming of the elderly human prostate into a primitive embryonic stem cell state - a model for prostatic development and carcinogenesis](#)
Deepali Pal, Northern Institute for Cancer Research, Newcastle University, UK
- 15.20 – 15.30 **Discussion**

Educational Workshops

Translation of radiation biology into meaningful clinical trials: All aboard!

Hosted by Ricky Sharma, University of Oxford, UK

08.00 – 08.45, Room 11

Speakers:

Introduction and overview

Ricky Sharma, University of Oxford, UK

PARP inhibition as an example of translation from preclinical models to clinical trials

Anthony Chalmers, University of Glasgow, UK

Clinical trials with radiotherapy: Keys to success

David Sebag-Montefiore, Leeds Teaching Hospitals NHS Trust, UK

Discussion

Ricky Sharma, University of Oxford, UK

Cutting edge translational research in head and neck cancer

Hosted by Hisham Mehanna, Institute of Head and Neck Studies and Education, Coventry, UK

11.00 – 15.00, Room 4

Objectives of the workshop:

1. Provide an update on cutting edge translational research in head and neck cancer (HNC) including deep sequencing, miRNA, mining public data bases.
2. Provide an update on developments in the field of HPV in HNC.
3. Provide a forum for young researchers to present their translational research in HNC.
4. Provide a platform for the development of collaborations between researchers and research groups in translational medicine in HNC.

Target audience:

1. Clinicians and researchers wishing to be updated on developments in translational research.
2. PhD and MSc students wishing to present their work in translational research in head and neck cancer.

Speakers:

Introduction: Working with the Head and Neck CSG and the Biomarker and Imaging CSG

Robert Brown, Imperial College London, UK and **Hisham Mehanna**, InHANSE University Hospitals Coventry and Warwickshire, Coventry, UK

Designing a translational project in cancer - what are the challenges and pitfalls? (Funding sources, the biomarker roadmap, reporting and more)

Andrew Hall, Newcastle Cancer Centre, UK



Keynote Lecture: The challenges of working at the frontier - deep sequencing in head and neck cancer²⁷

Jeff Myers, MD Anderson Cancer Center, Houston, USA

Recent developments in our understanding of HPV - head and neck cancer, epidemiology, mechanisms, treatments, vaccination...

Ned Powell, Cardiff University, UK

New biomarkers in head and neck cancer - methylation and miRNA

Mahyash Tavassoli, King's College London, UK

Harnessing the power of bioinformatics: Making use of high volume data analyses and mining public databases

Edward Curry, Imperial College London, UK

Summation

Gareth Thomas, University of Southampton, UK

Closed session (by invitation)

Delivering collaborations and high quality translational research in head and neck cancer - can we do it better?

Moderator: Richard Shaw, University of Liverpool, UK

Commercial Workshop

Headlines of International Conferences in 2012

Sponsored by Roche Products Limited

13.00 – 14.00, Room 11

What have been the latest developments in cancer research and treatment? Taking the data from past congresses, the Roche-sponsored symposium will present an independent view of the headline data from this year's key congresses.

Roche Products Limited welcomes all NCRI delegates to attend this Roche-sponsored symposium and hear from a clinician's perspective how the highlights of congresses such as the American Society of Clinical Oncology Annual Meeting could impact on patient care in the UK.

This symposium is sponsored by Roche Products Limited – with no editorial control on content



Afternoon Workshops

Improving the management of cerebral metastatic disease

Hosted by NCRI Brain Tumour Clinical Studies Group, UK

14.00 – 15.30, Room 12

The oncology team responsible for the primary cancer generally manages cerebral metastatic disease. Recent data suggests that management can be refined by more rigorous patient stratification and the application of a multimodal approach to treatment¹.

The purpose of this workshop will be to address the following questions:

1. Can we develop a national stratified approach to the management of cerebral metastatic cancer?



The workshop is aimed at oncologists, surgeons, nurses and pathologists involved in the management of patients with cerebral metastases. The overall aim is simple: "Can we do what we do better?"

References

1. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. *Journal of clinical oncology* : official journal of the American Society of Clinical Oncology. 2012 Feb 1;30(4):419-25.

Transforming oncology research: New models for novel therapeutic approaches

Hosted by French National Cancer Institute (INCa), France

14.00 – 15.30, Room 3B



The outstanding challenge in cancer research is to rapidly and cost-effectively translate the growing knowledge and developments in tumour biology and technology into new therapeutics.

The traditional preclinical models lack predictability for the clinical outcomes due to major differences in tumour biology, pathophysiology and tumour microenvironment. Similarly, small animals are insufficient for the development of new technologies for early detection of cancers.

Cancer is the commonest cause of death in dogs for which the main modalities of treatment are the same as in humans. Recently, comparative oncology studies (genetic, biological, clinical characterisation...) have revealed important similarities between canine tumours and corresponding human diseases and comparable responses to radiotherapy and systemic treatments. Taken together, canine spontaneous tumours have emerged as a promising model to bridge the gap between existing models and the clinic.

The support and the development of alternative preclinical models that better predict the clinical response to anti-cancer treatments was earmarked as a priority area in the 2009-2013 French Cancer Plan. Dedicated support to research projects involving vets, biologists and clinical teams has been provided for the last two years by Inserm and the French National Cancer Institute (INCa).

Since no European country has sufficient capacity to meet this objective alone, gathering resources at a European and international level is now necessary to pool skills and resources for joint research programs and collaboration. To this purpose, a European network, regrouping experts in basic and applied comparative oncology, is being set up to enlarge complementarities between human and veterinary research to develop new treatments, improving assessment and deciphering the molecular mechanisms underlying certain tumour types. The session hosted by INCa presents this network and the research objectives that would strengthen the link between existing preclinical models and human medicine by integrating naturally occurring canine cancers into cutting-edge translational cancer research.

Speakers:

Introduction

Robin Fahraeus, INSERM, Paris, France

Tumour biology and target identification

Ted Hupp, Edinburgh University, UK

Application of genomics technology in a consortium

Catherine Andre, CNRS, University of Rennes, France

Imaging, nanotechnologies and engineering applications

Annamarie Kristensen, The University of Copenhagen, Denmark

Nanoparticle based imaging of cells and tissue

Duncan Graham, The University of Strathclyde, UK

Transforming clinical practice through a clinical network

David Argyle, The University of Edinburgh, UK

Prize Winners Announcement

09.00 – 09.10 Prize Winners Announcement
Hall 1A

Plenary Lecture

Chaired by **Katherine Vallis**, Gray Institute for Radiation Oncology and Biology, Oxford, UK



09.10 – 09.50 Personalised genomic approaches and pathway identification for individualised prostate cancer therapy
Hall 1A

Robert G. Bristow, Ontario Cancer Institute/Princess Margaret Cancer Center & University of Toronto, Canada

Parallel Sessions

10.00 – 11.30 Assessing the economics of cancer care
Hall 1B **Hosted by Peter Smith**, Imperial College Business School & Centre for Health Policy, London, UK



10.00 – 11.30 Can this patient die comfortably at home?: Knowing the risks and what helps
Room 12

Hosted by Barbara Gomes, Cicely Saunders Institute, King's College London, UK



10.00 – 11.30 Clinical implications of clonal evolution and personalising therapy
Room 3A **Hosted by Faith Davies**, The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust, London, UK

10.00 – 11.30 Expanding the druggable genome
Room 3B **Hosted by Martin Drysdale**, The Beatson Institute for Cancer Research, Glasgow, UK

10.00 – 11.30 Prostate cancer: The androgen receptor takes centre stage
Room 4 **Hosted by Malcolm Mason**, Cardiff University, UK



10.00 – 11.30 Role of aspirin and other NSAIDs in cancer prevention
Hall 1A **Hosted by Jack Cuzick**, Wolfson Institute of Preventative Medicine, London, UK

10.00 – 11.30 Tumour angiogenesis
Room 11 **Hosted by Kairbaan Hodivala-Dilke**, Centre for Tumour Biology, Barts Cancer Institute, London, UK

Refreshment Break

11.30 – 11.50 Refreshment break
Registration area
& Galleria



Plenary Lecture

Chaired by Nic Jones, Manchester Cancer Research Centre and Cancer Research UK

11.50 – 12.30 **Functional genomics, experimental models and cancer**

Hall 1A **William Hahn**, Dana-Farber Cancer Institute, Boston, USA

Lunch

12.40 – 13.30 **Lunch** (*available to take away*)

Satellite symposia

13.30 – 16.30 **Satellite symposia**

KEY TO THEMES:

- **Diagnosis and therapy**
- **Epidemiology and prevention**
- **Survivorship and end-of-life care**
- **The cancer cell and model systems**
- **Information, patients and the public**
- **Tumour-specific research**

Assessing the economics of cancer care



- Hall 1B **Hosted by Peter Smith**, Imperial College Business School & Centre for Health Policy, London, UK
- 10.00 – 10.10 **Introduction**
Peter Smith, Imperial College Business School & Centre for Health Policy, London, UK
- 10.10 – 10.15 **The economics of survivorship**
Siobhan McClelland, Macmillan Cancer Support, London, UK
- 10.15 – 10.40 **Value of information analysis within a stakeholder-driven research prioritisation process: An application in cancer genomics**
Scott Ramsey, Fred Hutchinson Cancer Research Center & University of Washington, Seattle, USA
- 10.40 – 11.05 **The economic burden of cancer across the European Union**
Jose Leal, University of Oxford, UK
- 11.05 – 11.30 **Cancer services in England: Providing value for money?**
Peter Smith, Imperial College Business School & Centre for Health Policy, London, UK

Can this patient die comfortably at home?: Knowing the risks and what helps



- Room 12 **Hosted by Barbara Gomes**, Cicely Saunders Institute, King's College London, UK
- 10.00 – 10.15 **Introduction**
Barbara Gomes, Cicely Saunders Institute, King's College London, UK
- 10.15 – 10.40 **Cross-national variations in place of death of cancer patients**
Joachim Cohen, Vrije Universiteit Brussel, Brussels, Belgium
- 10.40 – 11.05 **Improving care delivery and personality care: Integrating ASyMS to cancer care**
Nora Kearney, University of Dundee, UK
- 11.05 – 11.30 **Promoting quality of life and care of advanced cancer patients: What factors matter most?**
Holly Prigerson, Dana-Farber Cancer Institute, Boston, USA

Clinical implications of clonal evolution and personalising therapy

- Room 3A **Hosted by Faith Davies**, The Institute of Cancer Research, London, UK
- 10.00 – 10.15 **Introduction**
Faith Davies, The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust, London, UK
- 10.15 – 10.40 **Risk-driven therapy in acute myeloid leukaemia**
Alan Burnett, Cardiff University, UK
- 10.40 – 11.05 **Founding clones and evolving subclones: Insights in acute myeloid leukaemia from next-generation sequencing**
John Welch, Washington University, St. Louis, USA
- 11.05 – 11.30 **The clinical impact of advances in the genetic understanding of cancer**
Gareth Morgan, The Institute of Cancer Research, London, UK



Expanding the druggable genome

- Room 3B **Hosted by Martin Drysdale**, The Beatson Institute for Cancer Research, Glasgow, UK
- 10.00 – 10.15 **Introduction**
Martin Drysdale, The Beatson Institute for Cancer Research, Glasgow, UK
- 10.15 – 10.40 **Enriching chemical space to drug undruggable targets**
David Spring, University of Cambridge, UK
- 10.40 – 11.05 **Drugging the undruggable: Small-molecule inhibition of Ras oncoprotein I**
Guowei Fang, Genentech/Roche, California, USA
- 11.05 – 11.30 **Bromodomain inhibitors extend the druggable genome: From phenotypic screening to first time in man**
Chun-wa Chung, GlaxoSmithKline, Stevenage, UK

Prostate cancer: The androgen receptor takes centre stage

- Room 4 **Hosted by Malcolm Mason**, Cardiff University, UK
- 10.00 – 10.15 **Introduction**
Malcolm Mason, Cardiff University, UK
- 10.15 – 10.40 **Androgen receptor co-regulatory proteins as alternative therapeutic targets in prostate cancer**
Craig Robson, Northern Institute for Cancer Research, Newcastle University, UK
- 10.40 – 11.05 **Biological insights arising from the identification of genes and pathways that are regulated by the androgen receptor**
Ian Mills, University of Oslo, Norway & Cancer Research UK Cambridge Research Institute, UK
- 11.05 – 11.30 **Targeting the androgen receptor in castration-resistant prostate cancer**
Gerhardt Attard, The Institute of Cancer Research, London, UK



Role of aspirin and other NSAIDs in cancer prevention

- Hall 1A **Hosted by Jack Cuzick**, Wolfson Institute of Preventative Medicine, London, UK

- 10.00 – 10.05 **Introduction**
Jack Cuzick, Wolfson Institute of Preventative Medicine, London, UK
- 10.05 – 10.30 **Aspirin and cancer: Evidence from randomised trials**
Nancy Cook, Brigham and Women's Hospital & Harvard Medical School, Boston, USA
- 10.30 – 10.55 **Aspirin and cancer risk: A meta-analysis to 2011**
Carlo LaVecchia, Istituto di Ricerche Farmacologiche Mario Negri & University of Milan, Italy
- 10.55 – 11.20 **Cancer prevention with aspirin: Randomised trial evidence**
John Burn, Newcastle University, UK
- 11.20 – 11.30 **Discussion**

Tumour angiogenesis

- Room 11 **Hosted by Kairbaan Hodivala-Dilke**, Centre for Tumour Biology, Barts Cancer Institute, London, UK
- 10.00 – 10.15 **Introduction**
Kairbaan Hodivala-Dilke, Centre for Tumour Biology, Barts Cancer Institute, London, UK
- 10.15 – 10.40 **Histidine-rich glycoprotein in tumour vessel normalisation and anti-tumour immune responsiveness**
Lena Claesson-Welsh, Uppsala University, Sweden
- 10.40 – 11.05 **Time to branch? Endothelial cell dynamics regulating vascular patterning**
Holger Gerhardt, Cancer Research UK London Research Institute, UK
- 11.05 – 11.30 **Tumour invasion and metastasis: Reduction by concurrent inhibition of c-MET and VEGF signalling**
Donald McDonald, University of California, San Francisco, USA